PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced new nonclinical data related to plixorafenib (FORE8394; formerly PLX8394), the company's novel, investigational, small-molecule, ...
BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...
A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor." As ...
“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” “This is the first report of spindle cell sarcoma BRAF ...
The genes encoding IDH1/2 and BRAF are frequently altered in low-grade glioma; the presence or absence of these alterations should be determined in all patients. Maximal safe tumor resection remains ...
In 1972, Janet Rowley sat at her dining room table and cut tiny chromosomes from photographs she had taken in her laboratory. One by one, she snipped out the small figures her children teasingly ...
This is a preview. Log in through your library . Abstract Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma—namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback